Literature DB >> 20101750

Tolvaptan and hyponatremia in a patient with cirrhosis.

Thomas D Boyer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20101750     DOI： 10.1002/hep.23522

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.

Authors:  Vishwadeep Ahluwalia; Douglas M Heuman; George Feldman; James B Wade; Leroy R Thacker; Edith Gavis; HoChong Gilles; Ariel Unser; Melanie B White; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2014-08-08       Impact factor: 25.083

2.  Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis.

Authors:  Brianna E Vaa; Sumeet K Asrani; Winston Dunn; Patrick S Kamath; Vijay H Shah
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

3.  Management of refractory ascites and hepatorenal syndrome.

Authors:  Amy N Sussman; Thomas D Boyer
Journal:  Curr Gastroenterol Rep       Date:  2011-02

4.  Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.

Authors:  Kota Shigeto; Takumi Kawaguchi; Takashi Niizeki; Yasushi Kunitake; Hidetoshi Takedatsu; Tatsuyuki Tonan; Kiminori Fujimoto; Masatoshi Tanaka; Toshi Abe; Hisanori Naito; Takuji Torimura
Journal:  Oncol Lett       Date:  2016-03-21       Impact factor: 2.967

5.  Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Authors:  Shahid Habib; Thomas D Boyer
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

Review 6.  Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

Authors:  Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

7.  The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Authors:  Tomomi Kogiso; Mutsuki Kobayashi; Kuniko Yamamoto; Yuichi Ikarashi; Kazuhisa Kodama; Makiko Taniai; Nobuyuki Torii; Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.